Author:
Rubia J. de la,Martín G.,Martínez J.,Lorenzo I.,Sanz G.,Jarque I.,Moscardó F.,Jiménez C.,Lorente P.,Camps A.,Sanz M. A.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Szer J, Juttner CA, To LB, et al. Post-remission therapy for acute myeloid leukemia with blood-derived stem cell transplantation: results of a collaborative phase II trial. Int J Cell Cloning. 1992; 10(suppl 1):114-116.
2. Reiffers J, Körbling M, Labopin M, Henon P, Gorin NC. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. Int J Cell Cloning. 1992;10(suppl 1):111-113.
3. Körbling M, Fliedner TM, Holle R, et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant. 1991;7:343-349.
4. Sanz MA, de la Rubia J, Sanz, et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol. 1993;11: 1661-1667.
5. Schiller G, Lee M, Miller T, et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission. Leukemia. 1997; 11:1533-1539.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献